Sign in
Taking people in United StatesNo phase

Reviews care pathways for newly diagnosed multiple myeloma in community cancer clinics

Looks back at records of adults with newly diagnosed multiple myeloma.

Key facts

Who runs it
All4Cure
Where
Seattle, United StatesSee the site
Trial code
Registry title
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma
Status
Recruiting
People taking part
450 people, planned
Started
18 Apr 2024
Expected to end
1 Dec 2026
Type of study
Observational, 3 groups
Treatments tested
  • Multiple Myeloma Pathway
  • All4Cure Platform
  • Documentation Pathway
Record updated
3 May 2024

Who can take part

AI summary

From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.

The trial is looking for adults newly diagnosed with multiple myeloma who receive care at a QCCA/Exigent Research practice. It reviews past medical records.

Age
18 years or older at diagnosis
Sex
All sexes can join
Disease stage
Newly diagnosed multiple myeloma, diagnosed on or after the launch of the MRD-targeted clinical pathway in the Exigent network. The diagnosis must be confirmed on review of the medical record.
Earlier treatment
No treatment for another cancer within three years before the myeloma diagnosis, except for some skin cancers and in situ breast or cervix cancers.

Main reasons for not taking part

  • Another cancer at the same time (except basal cell or squamous cell skin cancer, or in situ breast or cervix cancer)
  • Treatment for another cancer in the three years before diagnosis (same exceptions)
  • Myeloma subtype IgD or IgE
  • Moved care outside the QCCA/Exigent Research network within 90 days of diagnosis
  • Did not keep receiving care at a QCCA/Exigent Research practice for at least 90 days after the index date

The registry criteria, word for word

Show all 9 criteriaShow less

Who can take part

  • Diagnosis of multiple myeloma; Diagnosis must occur on or after the formal launch of the MRD-targeted clinical pathway in the Exigent network; Diagnosis must be indicated by the presence of any of the following diagnostic codes for multiple myeloma: [C90.00]; Diagnosis must be confirmed on human review of the medical record
  • Age ≥ 18 years at qualifying diagnosis
  • Patient has continued to receive care at a QCCA/Exigent Research practice for at least 90 days after the index date; Patients in the Documentation Cohort must meet the following additional inclusion criteria
  • Evidence in the record of a threshold level of adherence to the clinical pathway, or implied intention to adhere to the clinical pathway; In addition to the inclusion criteria for the documentation cohort, patients in the Platform Cohort must meet the following additional inclusion criteria
  • A record of registration by the patient for participation in the All4Cure platform, including signed HIPAA release forms that allow All4Cure to access their medical records
  • A record of registration by the patient's primary treating physician for participation in the All4Cure platform

Who cannot take part

  • Patients with a concurrent other malignancy (except basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancies of breast or cervix), or those who have received treatment of another malignancy within three years prior to diagnosis of multiple myeloma (except for treatment of basal cell carcinoma, squamous cell carcinoma of the skin, or in situ malignancies of breast or cervix), are excluded from eligibility
  • Patients with multiple myeloma subtypes Immunoglobulin D (IgD) or Immunoglobulin E (IgE) are excluded due to the very low rate of these subtypes
  • Patients who transfer their care to another facility outside the QCCA/Exigent Research network within the first 90 days after NDMM diagnosis are excluded

Where in United States

  • All4CureSeattle, United StatesContact: Jennifer WrenTaking people

About the trial

What the trial wants to find out

All4Cure is partnering with community oncology practices participating in the Quality Cancer Care Alliance (QCCA) and Exigent Research to develop a clinical pathway that standardizes the evaluation, treatment and ongoing management of patients with newly diagnosed multiple myeloma who wish to achieve and maintain MRD negativity.

Read full original descriptionShow less

This is a longitudinal retrospective study that will collect data from three separate cohorts of patients with newly diagnosed multiple myeloma (NDMM). The cohorts classify patients based on whether care is delivered under an intention to adhere to an MRD-targeted clinical pathway, and if so, whether the implementation of that clinical pathway occurs through participation in the All4Cure platform vs. through written documentation. The three cohorts are labeled: Platform, Documentation, and Off-Pathway.

The 3 groups in the trial

  • Platform

    Patients in this cohort are participating in the All4Cure platform and there has been an established intention to treat according to the clinical pathway. Additionally, the patient's primary physician will also be a participant in the All4Cure platform.

    Treatment: Multiple Myeloma Pathway and All4Cure Platform

  • Documentation

    Patients in this cohort are not participating in the All4Cure platform but there has been an established intention to treat according to the clinical pathway.

    Treatment: Multiple Myeloma Pathway and Documentation Pathway

  • Off-pathway

    Patients in this cohort are not participating in the All4Cure platform and there has not been in intention to treat according to the clinical pathway that has been established by a landmark time period.

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Print a page for my doctor

Data and sources

Registry record
Listed on ClinicalTrials.gov.
Official title
Evaluating the Uptake and Utility of Clinical Pathways for Newly Diagnosed Patients With Multiple Myeloma That Aim to Achieve and Maintain Measurable Residual Disease (MRD)-Negativity in Community Oncology Settings
Plain-language title
Reviews care pathways for newly diagnosed multiple myeloma in community cancer clinicsGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 12 November 2026.
Record updated
3 May 2024